Twist Bioscience Corp — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Twist Bioscience priced an underwritten public offering of 3,125,000 shares of common stock at $96.00 per share on August 4, 2026, generating gross proceeds of $300.0 million. The underwriters (Goldman Sachs, William Blair, Leerink Partners, Guggenheim Securities) received a 30-day option to purchase an additional 468,750 shares. Closing was scheduled for August 6, 2026. Proceeds will fund R&D, manufacturing capacity expansion, and working capital.
Why this rating
Material but non-transformational for $2.3B company. ~13% of market cap raised; funds growth but not game-changing; dilution is modest.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.